Bad Pharma

How Drug Companies Mislead Doctors and Harm Patients

Ben Goldacre

10 min read
42s intro

Brief summary

Bad Pharma argues that modern medicine is broken because the evidence used to approve and prescribe drugs is systematically distorted by pharmaceutical companies. By legally hiding negative trial results and manipulating study designs, the industry creates a false picture of drug safety and effectiveness.

Who it's for

This book is for anyone who wants to understand the systemic flaws in how drugs are tested, regulated, and marketed.

Bad Pharma

Audio & text in the Readsome app

How Medical Evidence Is Systematically Distorted

Modern medicine is built on the promise that treatments are prescribed based on fair and transparent tests. However, the reality is a broken system where the evidence used to make life-and-death decisions is systematically distorted. This is not a conspiracy but the result of a perversely designed infrastructure. When the data guiding a doctor’s hand is flawed, the consequences manifest as avoidable suffering and death for patients.

The core of the problem lies in how clinical trials are conducted and reported. Pharmaceutical companies frequently fund the research for their own products, leading to trials designed to flatter the drug. When these studies produce unflattering results, companies are often legally permitted to hide them. This selective publication creates a "publication bias" where doctors only see a filtered, positive version of a drug’s performance. From antidepressants to stockpiled flu medications, the true effectiveness and safety of common treatments remain obscured because the full data sets are withheld from the public and the medical community.

Regulatory bodies offer a thin line of defense, but their standards are often surprisingly low. New drugs are frequently required only to prove they are better than a placebo, rather than better than existing, effective treatments. Furthermore, regulators are often obsessively secretive, failing to share the data they do have with the doctors who need it. This lack of transparency means that even after a drug reaches the market, its long-term risks may go unnoticed for years because the wider scientific community is blocked from scrutinizing the evidence.

The distortion continues through the commercialization and marketing of medicine. Industry spending on marketing often doubles the budget for research and development, aimed at influencing doctors through sales representatives, sponsored "education," and ghostwritten academic papers. Because medical knowledge evolves rapidly, doctors trying to stay current are bombarded with information funded by the very companies selling the products. Fixing this requires more than just exposing bad actors; it demands a total restructuring of how we generate, share, and apply medical knowledge to ensure science serves the patient rather than the shareholder.

Full summary available in the Readsome app

Get it on Google PlayDownload on the App Store

About the author

Ben Goldacre

Ben Goldacre is a British physician, academic, and science writer who is the Bennett Professor of Evidence-Based Medicine and Director of the Bennett Institute for Applied Data Science at the University of Oxford. His work focuses on evidence-based medicine, informatics, and epidemiology, and he is known for critically examining the misuse of science and statistics by journalists, politicians, and pharmaceutical companies. Goldacre is a prominent public health campaigner and co-founder of the AllTrials campaign, which advocates for transparency in clinical trial data.

Similar book summaries